Children living with HIV currently have to wait many years to access the best new antiretroviral medicines (ARVs) being developed for adults. This is simply unacceptable. And a variety of actors – from pharmaceutical companies to government regulators – can and should take action to accelerate this onerous process.
Last month, as I boarded a flight to Tanzania, I reflected on my first visit to the country over 11 years ago. It was my first glimpse of the work the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) implements around the world. Before my visit, I could have never imagined the reach our organization. I also could have never imagined the impact of the support it was providing to communities in Tanzania that were energetic, empowered, and willing to work together. I had dubbed the theme of that trip “Together we can.”